Sunovion Respiratory Marketing Team
Sunovion Pharmaceuticals, Inc.
Denise Strauss, VP, Head of Marketing
Michael Gaines, Executive Director, Head of Respiratory Portfolio
Gerard Hernandez, Senior Director
Alex Marichal, Senior Director
Henry McMillan, Senior Director
Katie Marino, Director
Bryan Parker, Director
Scott Ellis, Director
Corey MacGregor, Associate Director
Sara Zwicker, Associate Director
Caesar Ruivivar, Associate Director
Daniel Yi, Associate Director
Yoshika Nayak, Associate Director
Dianel Yunes, Senior Product Manager
Terry McElhiney, Senior Administrative Assistant
Commercializing Innovative COPD Products
The Sunovion Respiratory Marketing Team is comprised of a growing number of hardworking, passionate brand experts, all of whom contribute unique expertise and perspective. Just three months into the year, the team has doubled in size from seven to 14 under Michael Gaines’s leadership, and tackled the first of four brand launches for 2017.
For more than 10 years, Sunovion Respiratory has been best known for its market leading nebulized long-acting beta2-adrenergic agonist (LABA). As the brand got older, it easily could have lost its shine—but thanks to this creative and resourceful brand team, product sales have grown to new heights due to the exploration of channels that had never been considered before.
Three million patients are hospitalized each year due to COPD-related exacerbations, some of whom then spend time in long-term care (LTC) facilities. With this in mind, the Sunovion team has made it a priority to create growth opportunities across diverse channels, and it’s paid off. In 2016, this product was the sixth best-selling COPD product. And, as if that weren’t enough, Sunovion is seeking approval of the first and only nebulized long-acting muscarinic antagonist (LAMA) for COPD in the later this year.
Most recently, Sunovion acquired three handheld inhaler products and is actively promoting one, with two other launches to follow later this year. These introduce an additional LABA option, a LAMA choice, and a fixed-dose treatment that delivers a LABA and LAMA combination through a single device.
This robust portfolio of products will enter a competitive and crowded market. Luckily, the Sunovion team has the passion, commitment, and expertise to drive these brands to success.